Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 5/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.45 |
| ▸ | MAPT | P10636 | 6/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | NAMPT | P43490 | 1/20 | 0.37 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3686150 | 0.85 | ALDH1A1 (0.51) | ALDH1A1HPGDMEN1KMT2AMAPT | |
| SCHEMBL109045 | 0.84 | ALDH1A1 (0.54) | ALDH1A1HPGDMEN1KMT2AMAPT | |
| SCHEMBL300884 | 0.83 | CA12 (0.42) | ALDH1A1HPGDMEN1KMT2AMAPT | |
| SCHEMBL7327634 | 0.82 | HPGD (0.46) | ALDH1A1HPGDMEN1KMT2AMAPT | |
| SCHEMBL10168511 | 0.81 | ALDH1A1 (0.47) | ALDH1A1HPGDMEN1KMT2AMAPT | |
| SCHEMBL20133945 | 0.81 | ALDH1A1 (0.43) | ALDH1A1HPGDMEN1KMT2AMAPT | |
| SCHEMBL7769437 | 0.81 | ALDH1A1 (0.54) | ALDH1A1HPGDMEN1KMT2AMAPT | |
| SCHEMBL8828394 | 0.81 | ALDH1A1 (0.45) | ALDH1A1HPGDMEN1KMT2AMAPT | |
| SCHEMBL14369503 | 0.81 | ALDH1A1 (0.58) | ALDH1A1HPGDMEN1KMT2AMAPT | |
| Hydrochloric Acid SCHEMBL9715221 | 0.81 | HPGD (0.45) | ALDH1A1HPGDMEN1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9394354-B2 | Haptens of paliperidone | JANSSEN PHARMACEUTICA NV (BE) | 2016-07-19 | — | — | US | disclosed |
| US-9394354-B2 | Haptens of paliperidone | JANSSEN PHARMACEUTICA NV (BE) | 2016-07-19 | — | — | US | disclosed |
| US-20140213767-A1 | HAPTENS OF PALIPERIDONE | ORTHO-CLINICAL DIAGNOSTICS, INC. (US) | 2014-07-31 | — | — | US | disclosed |
| US-20140213767-A1 | HAPTENS OF PALIPERIDONE | ORTHO-CLINICAL DIAGNOSTICS, INC. (US) | 2014-07-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140213767-A1 | HAPTENS OF PALIPERIDONE | CD274, PIN1, LY96 | ALDH1A1 327/4885HPGD 1103/4885MEN1 3657/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.